Select to view the solutions available in your location.
Track orders, get results, manage personal information, and more.
Order tests, track orders, get results, and more.
Learn more about our innovative products and services that help detect cancer earlier and power smarter treatment decisions.
Exact Sciences plans to introduce the Cologuard Plus™ test in 2025, building on a decade of patient impact.
Find out how our scientific rigor, quality standards, and development of future tests make us a leader in cancer testing and treatment guidance.
How one revolutionary test could change the health of millions.
Learn all about Exact Sciences, including our purpose, the people who drive it, our history, and the impact we’ve made.
Several Exact Sciences initiatives address disparities in cancer outcomes among U.S. Latinos.
Explore stories, news, and events that highlight our innovation, technology, and people fighting cancer on all fronts.
Approximately 20% of all new breast cancers diagnosed in the United States are ductal carcinoma in situ (DCIS),1 and no two DCIS patients—or their tumors—are the same.
A pre-invasive form of breast cancer in which tumor cells are confined within the milk ducts, DCIS is typically non-lethal but treatments—such as surgery, radiation therapy, and hormonal therapy—can cause both short term and long-term side effects.
Exact Sciences’ Oncotype DX Breast DCIS Score® test enables women and their doctors to personalize their treatment decisions and potentially forgo unnecessary treatment, such as radiation, when they have a low score and a low risk of local recurrence. For those with higher scores, the result confirms that they would indeed benefit from a more aggressive local approach to treatment, such as radiation therapy.
1American Cancer Society. https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/types-of-breast-cancer/dcis.html